Muscular dystrophy gene therapy (Asklepios)

N/A

Report date: 2023/10/26 16:40:24

Base Information

Drug NameMuscular dystrophy gene therapy (Asklepios)
Drug Alias NamerAAV2.5-CMV-minidystrophin (d3990)Biostrophin
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transferenceDystroglycan stimulants
TargetsDystroglycan
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAskBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAskBio Inc
Active IndicationsN/A
Inactive IndicationsMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A